Previous close | 68.12 |
Open | 68.17 |
Bid | 0.00 x 800 |
Ask | 0.00 x 900 |
Day's range | 67.46 - 68.33 |
52-week range | 48.35 - 69.21 |
Volume | |
Avg. volume | 6,341,959 |
Market cap | 99.894B |
Beta (5Y monthly) | 0.79 |
PE ratio (TTM) | 63.51 |
EPS (TTM) | 1.07 |
Earnings date | 24 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 73.75 |
The U.S. Food and Drug Administration on Wednesday classified a recall of Boston Scientific's device used to block blood flow during excessive bleeding or hemorrhaging as "most serious". An investigation showed that Boston's device, Obsidio Embolic, when used with a specific technique posed a higher risk of bowel ischemia during procedures to stop gastrointestinal (GI) bleeding, the agency said. Bowel ischemia describes disorders that occur when blood flow to your intestines decrease, causing severe abdominal pain.
Boston Scientific (BSX) is expected to have registered strong growth in the Asia Pacific, led by strength in China, Japan and Latin America.
This article delves into the examination of the 14 best 52-week high stocks to buy now. To explore more such companies that meet comparable criteria, go directly to 5 Best 52-Week High Stocks To Buy Now. The outlook for 2024 is positive for the economy and the stock market. Market conditions improved significantly in Q4 […]